Evotec (NASDAQ:EVO) & InterCure (NASDAQ:INCR) Head to Head Analysis

Evotec (NASDAQ:EVO) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider & Institutional Ownership

5.8% of Evotec shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 1.0% of Evotec shares are owned by company insiders. Comparatively, 0.2% of InterCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Evotec and InterCure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evotec	N/A	N/A	N/A
InterCure	N/A	N/A	N/A

Earnings and Valuation

This table compares Evotec and InterCure’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$791.73 million	2.25	-$185.07 million	N/A	N/A
InterCure	$115.83 million	1.05	$13.36 million	$0.13	20.46

InterCure has lower revenue, but higher earnings than Evotec.

Analyst Recommendations

This is a summary of current ratings and target prices for Evotec and InterCure, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	0	0	3	0	3.00
InterCure	0	0	0	0	N/A

Evotec presently has a consensus price target of $11.00, suggesting a potential upside of 119.12%. Given Evotec’s higher possible upside, equities research analysts clearly believe Evotec is more favorable than InterCure.

Volatility & Risk

Evotec has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500.

Summary

Evotec beats InterCure on 5 of the 8 factors compared between the two stocks.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.